Biolase on Nov. 7 sold roughly 14.2 million shares at $2.39 apiece, along with warrants to purchase up to 9.2 million additional shares at an exercise price of $4 a share. The warrants expire Nov. 7, 2017.
If all the warrants are exercised, Biolase said will receive an additional $36.8 million in gross proceeds, bringing the gross value of the transaction up to $71.8 million.
Investors included Biolase chairman Paul Clark, CEO Jeffrey Nugent and director Dr. Jonathan Lord, along with the Schuler Family Foundation, Jack Schuler, Oracle Partners, Oracle Institutional Partners and the Oracle Ten Fund Master, according to a Nov. 3 regulatory filing.
Biolase said the 3 Oracle affiliates collectively owned a 19.1% stake prior to the private placement and had nominated Lord to its board. Entities associated with Jack Schuler owned 5.9% before the latest transaction, the company said.
Biolase said it plans to use net proceeds from the placement for general corporate purposes.
This is the 2nd time in recent months that Jack Schuler and Oracle affiliates have been part of a Biolase private placement. In July, they joined Birchview Capital and various Biolase directors and officers in purchasing $12 million in unregistered shares.
Meanwhile, Biolase’s board has been battling with former chairman & CEO Frederico Pignatelli over the company’s corporate governance. Pignatelli resigned as CEO and Chairman in June after many years with the company. Pignatelli reported owning 1.8 million shares of BIOL stock in August.